Editas Medicine Liabilities 2024

Editas Medicine Aktienanalyse

What does Editas Medicine do?

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Editas Medicine's Liabilities

Editas Medicine's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Editas Medicine's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Editas Medicine's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Editas Medicine's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Editas Medicine’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Editas Medicine Stock

What is the level of liabilities of Editas Medicine this year?

Editas Medicine has a debt balance of 150.06 M USD this year.

What were the liabilities of Editas Medicine compared to the previous year?

The liabilities of Editas Medicine have increased by -2.31% dropped compared to the previous year.

What are the consequences of high debt for investors of Editas Medicine?

High liabilities can pose a risk for investors of Editas Medicine, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Editas Medicine?

Low liabilities mean that Editas Medicine has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Editas Medicine affect the company?

An increase in liabilities of Editas Medicine can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Editas Medicine affect the company?

A decrease in the liabilities of Editas Medicine can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Editas Medicine?

Some factors that can influence the liabilities of Editas Medicine include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Editas Medicine so important for investors?

The liabilities of Editas Medicine are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Editas Medicine take to modify the liabilities?

To change its liabilities, Editas Medicine can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Editas Medicine in the year 2023?

In the year 2023, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.